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Abstract 
Background: Goals of management in patients with heart failure and reduced ejection fraction 
(HFrEF) include reducing death and hospitalizations, and improving health status (symptoms, 
physical function and quality of life). In the Dapagliflozin And Prevention of Adverse-outcomes 
in Heart Failure (DAPA-HF) trial, sodium–glucose cotransporter-2 inhibitor, dapagliflozin, 
reduced death and hospitalizations, and improved symptoms in patients with HFrEF. In this 
analysis, we examine the effects of dapagliflozin on a broad range of health status outcomes, 
using the Kansas City Cardiomyopathy Questionnaire (KCCQ).  
Methods: KCCQ was evaluated at randomization, 4 and 8 months. Patients were divided by 
baseline KCCQ total symptom score (TSS); Cox proportional hazards models examined the 
effects of dapagliflozin on clinical events across these subgroups. We also evaluated the effects 
of dapagliflozin on KCCQ-TSS, clinical summary score (CSS) and overall summary score 
(OSS). Responder analyses were performed to compare proportions of dapagliflozin vs. placebo-
treated patients with clinically meaningful changes in KCCQ at 8 months. 
Results: 4443 patients had available KCCQ at baseline (median KCCQ-TSS 77.1 [IQR 58.3–
91.7]). The effects of dapagliflozin versus placebo on reducing cardiovascular death or 
worsening HF were consistent across the range of KCCQ-TSS (lowest to highest tertile: HR 
(95% CI) 0.70 (0.57–0.86); 0.77 (0.61–0.98); 0.62 (0.46–0.83); P for heterogeneity=0.52). 
Patients treated with dapagliflozin had greater improvement in mean KCCQ-TSS, -CSS and -
OSS at 8 months (2.8, 2.5 and 2.3 points higher vs. placebo; P <0.0001 for all). Fewer patients 
treated with dapagliflozin had a deterioration in KCCQ-TSS (OR 0.84, 95% CI 0.78–0.90; 
P<0.0001); and more patients had at least small, moderate and large improvements (OR, 95% CI: 
1.15, 1.08–1.23; 1.15 (1.08–1.22); 1.14 (1.07–1.22); number-needed-to-treat=14, 15 and 18, 
respectively; P<0.0001 for all; results consistent for KCCQ-CSS and -OSS). 
Conclusions: Dapagliflozin reduced cardiovascular death and worsening HF across the range of 
baseline KCCQ, and improved symptoms, physical function and quality of life in patients with 
HFrEF. Furthermore, dapagliflozin increased the proportion of patients experiencing at least 
small, moderate and large improvements in health status; these effects were clinically important.   
Clinical Trial Registration: URL: https://clinicaltrials.gov; Unique Identifier: NCT03036124. 
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Non-standard Abbreviations and Acronyms 
ACEI: Angiotensin-converting enzyme Inhibitor  
ARB: Angiotensin II receptor blockers 
ARNI: Angiotensin receptor neprilysin inhibitor 
BP: Blood pressure 
CABG: Coronary artery bypass grafting  
CI: Confidence interval 
CRT-D: cardiac resynchronization therapy defibrillator 
CRT-P: cardiac resynchronization therapy pacemaker 
CSS: Clinical summary score  
CV: Cardiovascular 
DAPA-HF: Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure 
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DEFINE-HF: Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients 
With Heart Failure with Reduced Ejection Fraction  
eGFR: Estimated glomerular filtration rate 
HF: Heart failure 
HF-ACTION: Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training 
HFrEF: Heart failure and reduced ejection fraction 
HR: Hazard ratio 
ICD: implantable cardioverter defibrillator 
IQR: Interquartile range 
KCCQ: Kansas City Cardiomyopathy Questionnaire 
LBBB: Left bundle branch block 
LVEF: Left ventricular ejection fraction  
MADIT-CRT: Multicenter Automatic Defibrillator Implantation Trial With Cardiac 
Resynchronization Therapy 
NNT: Number-needed-to-treat  
NT-proBNP: N-terminal pro-B-type natriuretic peptide 
NYHA: New York Heart Association  
OR: Odds ratio 
OSS: Overall summary score 
PARADIGM-HF: Prospective comparison of ARNI (Angiotensin Receptor Neprilysin Inhibitor) 
with ACEI (Angiotensin-Converting-Enzyme Inhibitor) to Determine Impact on Global 
Mortality and Morbidity in Heart Failure 
PCI: Percutaneous coronary intervention  
SGLT2i: sodium–glucose cotransporter-2 inhibitor 
SHIFT: Systolic Heart Failure Treatment with the If inhibitor ivabradine 
TSS: Total symptom score 
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Clinical Perspective 
 
What is new? 
• Dapagliflozin improved cardiovascular death or worsening heart failure in patients with 
heart failure and reduced ejection fraction regardless of the level of symptomatic 
impairment at baseline 
• Dapagliflozin improved symptom burden, physical function and quality of life in patients 
with heart failure and reduced ejection fraction; these effects were sustained and 
amplified over time 
• Dapagliflozin significantly increased the proportion of patients experiencing at least 
small, moderate and large improvements in health status; these effects were clinically 
important 
 
What are the clinical implications? 
• The beneficial effects of dapagliflozin on heart failure outcomes are independent of the 
health status impairment at baseline 
• Our findings indicate that dapagliflozin significantly improves heart failure-related health 
status (symptoms, physical function and quality of life), as measured by Kansas City 
Cardiomyopathy Questionnaire, with the benefits emerging early and being sustained 
long-term 
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Introduction  
Patients with heart failure and reduced ejection fraction (HFrEF) are at high risk of disease 
progression, resulting in clinical deterioration, repeat hospitalizations and death1. Importantly, 
they also experience a high burden of debilitating symptoms, which impact their daily function 
and quality of life. Of note, some treatments for HFrEF (such as beta blockers) that have a 
favorable effect on death and hospitalizations do not improve health status2, highlighting the high 
unmet need for additional efficacious therapies that not only improve clinical events, but also 
reduce symptom burden and physical limitations, and improve the quality of life. In fact, 
improving patients’ health status (which includes symptom burden, physical limitations and 
quality of life) is a key goal of heart failure management, increasingly recognized by the practice 
guidelines3, 4, and acknowledged by regulators as an important outcome5. 
 In the placebo-controlled Dapagliflozin And Prevention of Adverse-outcomes in Heart 
Failure (DAPA-HF) trial, the sodium–glucose cotransporter-2 inhibitor, dapagliflozin, added to 
other guideline-recommended therapies, reduced the risk of mortality and heart failure 
hospitalization, and improved symptoms in 4744 patients with HFrEF6. In the current analysis, 
we sought to address the following two objectives: 1) to evaluate whether the effects of 
dapagliflozin on clinical outcomes in the DAPA-HF trial varied according to the degree of 
symptomatic impairment at baseline; and 2) to examine the effects of dapagliflozin on the broad 
range of health status outcomes, as measured by the various domains of the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) – a validated, self-administered instrument that 
quantifies heart failure related symptoms, function and quality of life. 
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Methods 
Data underlying the findings described in this manuscript may be obtained in accordance with 
AstraZeneca’s data sharing policy7. DAPA-HF was a randomized, double-blind, controlled trial 
in patients with HFrEF, which evaluated the efficacy and safety of dapagliflozin 10 mg once 
daily, compared with matching placebo, added to standard care. The design, baseline 
characteristics, and primary results of the trial have been published8. The Ethics Committee of 
each of the 410 participating institutions (in 20 countries) approved the protocol, and all patients 
gave written informed consent. The corresponding author had full access to all of the trial data 
and takes responsibility for its integrity and the data analysis. 
Study patients 
Men and women aged ≥18 years with heart failure (HF) were eligible if they were in New York 
Heart Association (NYHA) functional class ≥II, had a left ventricular ejection fraction ≤40%, 
and were optimally treated with pharmacological and device therapy for HF. Participants were 
also required to have a N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration 
≥600 pg/mL (≥400 pg/mL if hospitalized for HF within the previous 12 months). Patients with 
atrial fibrillation or atrial flutter were required to have a NT-proBNP level ≥900 pg/mL, 
irrespective of history of HF hospitalization. Key exclusion criteria included: symptoms of 
hypotension or systolic blood pressure <95 mmHg, estimated glomerular filtration rate (eGFR) 
<30 mL/min/1.73m2 (or rapidly declining renal function), type 1 diabetes, and other conditions 
likely to prevent patient participation in the trial or greatly limit life expectancy. A full list of 
exclusion criteria is provided in the design manuscript9. 
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Study procedures 
After the provision of informed consent, visit 1 started a 14-day screening period during which 
the trial inclusion and exclusion criteria were checked, and baseline information were collected. 
Visit 2 was the randomization visit and randomization was stratified based on diagnosis of type 2 
diabetes (defined as an established diagnosis or a glycated haemoglobin level of ≥6.5% [≥48 
mmol per mole]). After randomization, follow-up visits took place at 14 and 60 days, and then at 
120, 240, 360 days and every four months thereafter. The visit early after randomization (14 
days) was included to check renal function and blood pressure (as well as for symptoms of 
hypotension); this visit also allowed for adjustment of background diuretic or other non-essential 
therapies. Dose reduction (to 5mg daily of dapagliflozin or placebo) or temporary 
discontinuation of study drug was to be considered in case of an acute unexpected decline in 
eGFR, volume depletion or hypotension (or to avoid these conditions); however, dose up-
titration (or re-initiation) was encouraged thereafter in all cases, where possible. 
Clinical outcomes 
The primary outcome in the DAPA-HF trial was the composite of an episode of worsening heart 
failure (HF hospitalization or urgent HF visit) or cardiovascular (CV) death, whichever occurred 
first. Additional clinical outcomes assessed in the current study were the occurrence of HF 
hospitalization or CV death; worsening HF events (HF hospitalizations or urgent HF visits), 
hospitalization for HF, CV death, and all-cause death.  
Kansas City Cardiomyopathy Questionnaire 
The KCCQ was completed electronically by patients, without assistance by site study staff (as 
validated), and evaluated at randomization, 4-months and 8-months. The KCCQ is a 23-item, 
self-administered disease-specific instrument that quantifies symptoms (frequency, severity and 
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recent change), physical function, quality of life, and social function over the prior 2 weeks. In 
the KCCQ, the total symptom score (TSS) quantifies the symptom frequency and severity, 
KCCQ clinical summary score (CSS) includes the physical function and symptoms domains, and 
KCCQ overall summary score (OSS) is derived from the following domains (total symptom 
score, physical function, quality of life and social function). For each domain, the validity, 
reproducibility, responsiveness and interpretability have been independently established. Scores 
are transformed to a range of 0–100, in which higher scores reflect better health status10.  
Statistical analysis 
In the present post-hoc analysis, patients were divided into three subgroups, based on the tertiles 
of baseline KCCQ-TSS (which was the KCCQ domain pre-specified as the secondary endpoint): 
(i) ≤65.6, (ii) 65.7–87.5, (iii) >87.5 points. Baseline characteristics were summarized as means
and standard deviations, medians, and interquartile ranges, or percentages. A Cuzick extension of 
the Wilcoxon test for trend was used to compare trends across categories of KCCQ11. The rates 
of CV death and worsening HF across the tertiles of KCCQ-TSS (regardless of treatment 
allocation) were calculated and compared using Kaplan–Meier estimates. 
To compare the effects of dapagliflozin vs placebo on clinical outcomes across the 
KCCQ-TSS tertiles, we evaluated time-to-event data with the use of Kaplan–Meier estimates and 
used Cox proportional-hazards models, stratified according to diabetes status, with a history of 
HF hospitalization and treatment-group assignment as fixed-effect factors to calculate hazard 
ratios (HR), 95% confidence intervals (CI), and two-sided P values.  
We analyzed the differences between treatment groups in mean KCCQ-TSS, CSS and 
OSS at 4 months and 8 months in surviving patients, using a mixed model for repeated 
measurements and estimated the least-squares mean differences between treatment groups 
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adjusted for baseline KCCQ values. We conducted responder analyses examining proportions of 
patients with a deterioration, and clinically important improvements in KCCQ at 8 months. We 
used established, clinically meaningful thresholds for KCCQ (≥5 point [at least small], ≥10 point 
[moderate], and ≥15 point [large] change) for all responder analyses across the KCCQ 
domains12. The proportion of responders was compared between those treated with dapagliflozin 
versus placebo using multiple imputation to account for missing KCCQ values (see below). Odds 
ratios (OR) to estimate differences between treatment groups, and their corresponding 95%CI 
and 2-sided p-values were estimated from logistic regression models (which included treatment 
group, stratification variable (type 2 diabetes at randomization) and baseline KCCQ values); the 
models used imputed data accounting for missing KCCQ values and estimates were combined 
using Rubin’s rules. Missing data were imputed using a missing at random assumption and a 
predictive mean matching multiple imputation model, and a method of Fully Conditional 
Specification as implemented in the SAS Procedure MI (FCS statement). The imputation model 
included the treatment group, type 2 diabetes randomization stratum, KCCQ scores at baseline, 4 
months, and 8 months, and a categorical variable representing the number of investigator 
reported HF events (0, 1, ≥2 events) in the interval from randomization to 4 months, and in the 
interval from 4 to 8 months. Patients who died were counted as not improved in the analysis of 
improvement, or deteriorated in the analysis of deterioration. Patients with a baseline KCCQ 
score which was too high for them to experience an improvement according to a certain 
threshold (e.g, baseline score ≥95 points for the 5 point threshold) were defined as improved if 
their score remained high ( i.e, ≥95 points) at 8 months. Similarly, patients with at KCCQ score 
at baseline which was too low for them to experience a deterioration were defined as deteriorated 
if their score remained low at 8 months. Number-needed-to-treat (NNT) with their corresponding 
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95%CI were calculated using the method described by Bender13. All analyses were conducted 
using STATA version 15.1 (College Station, TX, USA) and SAS version 9.4 (SAS Institute, 
Cary, NC,USA). A P-value of 0.05 was considered statistically significant. 
Results  
Patient characteristics 
Overall, 4443 patients (93.7% of the overall trial population) had available KCCQ data at 
baseline. Baseline characteristics of patients with recorded versus missing KCCQ-TSS at 
randomization are presented in Supplemental Table 1. There were a few modest differences 
between those with and without available KCCQ-TSS at baseline, although most clinical 
characteristics were similar. Notably, patients randomized to dapagliflozin versus placebo were 
equally distributed among those with recorded and missing KCCQ-TSS at baseline. Importantly, 
there was also no difference in clinical outcomes between patients that had KCCQ-TSS recorded 
versus missing at randomization (Supplemental Table 2). Of these, 4141 patients (89.7% of 
surviving patients) had KCCQ evaluated at 4 months (130 missing KCCQ data due to death, 473 
missing for reasons other than death); and 3955 (88.3% of surviving patients) had KCCQ 
evaluated at 8 months (257 missing KCCQ data due to death, 532 missing KCCQ data for 
reasons other than death). The proportions of patients with missing KCCQ values were similar in 
the dapagliflozin and placebo groups at 4 months and 8 months (89.9% versus 89.6%; and 88.7% 
versus 87.6%, respectively). The median KCCQ-TSS was 77.1 (interquartile range 58.3–91.7). 
The number and proportion of patients in the KCCQ-TSS tertiles are shown in Table 1. 
Compared to participants with higher KCCQ-TSS scores at baseline, those with lower scores 
were younger, more often women, white, and enrolled in Europe and the Americas (and less 
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likely to be enrolled in Asia – observation also made in prior HFrEF global trials14). They also 
had a higher body mass index, and natriuretic peptide levels; and a lower eGFR (Table 1); more 
likely to be in NYHA functional class III/IV, than in class II, and to have type 2 diabetes and 
atrial fibrillation. With respect to background HF medications, patients with lower baseline 
KCCQ-TSS were more frequently treated with mineralocorticoid receptor antagonists and 
diuretics. Baseline use of angiotensin receptor neprilysin inhibitor was generally low but similar 
across age groups. The proportion of patients treated with implantable cardiac devices was 
generally comparable across the KCCQ-TSS subgroups.  
Clinical outcomes 
Patients with lower baseline KCCQ-TSS experienced higher rates of CV death or worsening HF 
(25.0%, 17.3% and 13.6% in patients across KCCQ-TSS tertiles of ≤65.6, 65.7–87.5, >87.5, 
respectively; P <0.001). In the Cox proportional hazards models, patients with lower baseline 
KCCQ-TSS had a higher risk of CV death or worsening HF (Tertile >87.5: Referent; Tertile 
65.7–87.5: HR 1.30 (95%CI: 1.08–1.56), p=0.006; Tertile ≤65.6: HR 1.93 (95%CI 1.62–2.30), 
p<0.001; Figure 1). 
The effects of dapagliflozin on the range of clinical outcomes are summarized in Figure 
2. Dapagliflozin reduced the primary outcome of CV death or worsening HF across the entire 
range of KKCQ-TSS, with no evidence of treatment effect heterogeneity; and with patients in 
each tertile experiencing a statistically significant benefit (HR [95% CIs] from lowest to highest 
tertile: 0.70 [0.57–0.86], 0.77 [0.61–0.98], and 0.62 [0.46–0.83], respectively; P for 
heterogeneity = 0.52). Similar results were observed for CV death or hospitalization for HF; 
worsening HF events; HF hospitalizations; CV death; and all-cause death (Figure 2; all P values 
for heterogeneity non-significant).  
D
ow
nloaded from
 http://ahajournals.org by on December 17, 2019
10.1161/CIRCULATIONAHA.119.044138 
12 
Health status outcomes 
The mean changes in KCCQ-TSS, -CSS and -OSS over time are presented in Figure 3 (Panels A, 
B, C, respectively). Patients treated with dapagliflozin had a modest, but significant 
improvement in mean KCCQ-TSS, -CSS and -OSS at 4 months (1.9, 1.8 and 1.7 points higher 
than placebo, respectively; P < 0.0001 for all). These differences between dapagliflozin and 
placebo were amplified over time, with the corresponding mean differences at 8 months being 
2.8, 2.5 and 2.3 points higher in favor of dapagliflozin vs. placebo (P<0.0001 for all).  
The results of the responder analysis are shown in Figure 4 (Panels A–D). Fewer patients treated 
with dapagliflozin had a clinically significant deterioration (≥5 point decline in KCCQ-TSS 
(25.3% vs 32.9%; OR 0.84, 95% CI 0.78–0.90; p<0.0001); and more patients treated with 
dapagliflozin had at least small (58.3% vs 50.9%), moderate (54.5% vs 47.6%), and large (54.0% 
vs 48.2%) improvements (corresponding OR, 95%CI: 1.15, (1.08–1.23); 1.15 (1.08–1.22); 1.14 
(1.07–1.22); NNT (95% CI) = 14 (10–23), 15 (11–25) and 18 (12–35), respectively; P<0.0001 
for all; Figure 4, panels A–B). The findings were similar for KCCQ-CSS and -OSS (Figure 4, 
panels C–F). 
Discussion 
In this prospective study, which evaluated pre-specified assessments of health status using 
KCCQ in the DAPA-HF trial, we observed that treatment with dapagliflozin reduced the risk of 
all key clinical events, including the primary composite endpoint of CV death or worsening HF, 
and its components, to a similar extent across the entire range of KCCQ at baseline, indicating 
that the beneficial effects of dapagliflozin on HF outcomes are independent of the health status 
impairment at baseline. Furthermore, dapagliflozin significantly improved KCCQ-TSS, -CSS 
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and -OSS (which collectively encompass symptoms, physical function, quality of life, and social 
function), and these effects were amplified over time. Finally, significantly fewer patients treated 
with dapagliflozin experienced clinically meaningful deterioration, and significantly more 
experienced at least small, moderate and large clinically meaningful improvements in health 
status. These effects were substantial, with NNT ranging between 12 and 18 after just 8 months 
of treatment. 
Our results have several important implications. First, our analyses of the clinical 
outcomes across the subgroups of baseline KCCQ-TSS show no evidence of heterogeneity in the 
benefit of dapagliflozin by the magnitude of symptomatic impairment at baseline. Previously 
reported pre-specified subgroup analyses of the primary endpoint (CV death or worsening HF) 
suggested that the benefit of dapagliflozin may be more pronounced in patients with NYHA class 
II vs class III-IV6. However, NYHA class, while prognostically important, represents a more 
subjective, arbitrary and non-patient-centric assessment of symptom burden; and considering this 
report, the observation from the prior NYHA class subgroup analysis was likely a chance 
finding. 
Second, our findings substantially expand on the previously reported effects of 
dapagliflozin on health status, as measured by KCCQ, in patients with HFrEF. In the 
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart 
Failure with Reduced Ejection Fraction (DEFINE-HF) trial, a modestly sized randomized, 
placebo-controlled trial performed across 26 sites in the United States, dapagliflozin was also 
shown to have favorable effects on several domains of KCCQ – with slightly greater mean 
differences in favor of dapagliflozin vs placebo (i.e. 4.8 points for KCCQ-TSS) than those 
observed in the DAPA-HF trial, but comparable responder analyses and NNT (i.e. NNT of 10 for 
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5 point or greater improvement in KCCQ-OSS), after just 12 weeks of treatment15. Our findings 
confirm these beneficial effects on symptoms, function and quality of life in a much larger, 
global trial, with a longer duration of follow up and the ability to assess the effects of 
dapagliflozin on clinical outcomes across the range of baseline KCCQ. Collectively, these 
complimentary findings from both the DEFINE-HF and DAPA-HF trials indicate that 
dapagliflozin significantly improves HF-related health status, as measured by KCCQ, with the 
benefits emerging early and being sustained long term. 
Third, the magnitude of the improvement in KCCQ that we observed with dapagliflozin 
vs placebo in the DAPA-HF trial compare favorably with other efficacious therapies for HFrEF. 
As an example, in the Systolic Heart Failure Treatment with the If inhibitor ivabradine Trial 
(SHIFT)16, ivabradine demonstrated a 2.4 point mean improvement in KCCQ-OSS, and 1.8 point 
mean improvement in KCCQ-CSS after 12 months of treatment. In the Prospective comparison 
of ARNI (Angiotensin Receptor Neprilysin Inhibitor) with ACEI (Angiotensin-Converting-
Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure 
(PARADIGM-HF) study17, sacubitril-valsartan demonstrated a 1.3- and 0.9-point improvements 
in KCCQ-OS and KCCQ-CS respectively, over enalapril after 8 months of treatment (although 
true baseline measurement of KCCQ was not done, which complicates the interpretation of these 
data). In the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-
ACTION) trial, exercise therapy in HFrEF produced a 1.9 point improvement in KCCQ-OSS18. 
In the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization 
Therapy (MADIT-CRT) study19 in patients with HFrEF and prolonged QRS interval, treatment 
with cardiac resynchronization therapy resulted in 2.0, 2.0 and 2.4 point improvements in 
KCCQ-TSS, -CSS and -OSS, respectively, in patients with left bundle branch block (LBBB), 
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and no significant improvements in KCCQ among patients without LBBB. It should be noted, 
however, that comparisons of mean between-group differences in KCCQ do not adequately 
reflect clinically important changes in individual patients (since the effects are averaged across 
large populations). Therefore, from a clinical standpoint, the responder analyses which calculate 
the proportions of individual patients that experience a clinically meaningful change 
(deterioration or improvement in KCCQ) are more informative. Although few responder 
analyses had been done previously, the magnitude of benefit (including NNT) observed with 
dapagliflozin in the responder analyses of DAPA-HF also compare very favorably with 
previously observed results16, 17. It should also be noted that the NNT for clinically meaningful 
improvements in KCCQ are based on comparisons of dapagliflozin-treated with placebo-treated 
patients (that also experienced an improvement in health status, consistent with a sizable 
“placebo effect”, seen both in our study, in the DEFINE-HF trial with dapagliflozin, and 
placebo-controlled trials of other agents in HFrEF16). Therefore, the magnitude of dapagliflozin 
effects on the health status in clinical practice (where, obviously, no placebo is used) may be 
even greater than that observed in this study. Given the importance of reducing symptom burden 
and functional limitations and improving the quality of life – a key goal of HF management 
endorsed by the practice guidelines and regulators – our findings provide further support for 
dapagliflozin as a new treatment option for patients with HFrEF. 
The results of our study should be considered in the context of several potential 
limitations. Although KCCQ was a pre-defined secondary endpoint, and prospective assessments 
of health status were specified in protocol, the evaluation of clinical outcomes (such as CV death 
or worsening HF) by tertiles of baseline KCCQ-TSS was done post hoc. The number of African 
American patients was relatively small, although similar to other global HFrEF trials. KCCQ 
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data were missing in a small proportion of patients. As in other trials, the pre-specified inclusion 
and exclusion criteria will have reduced enrolment of hospitalized, and other very high-risk, 
patients. These limitations may affect the generalizability of our results.  
Conclusions 
In the DAPA-HF trial, treatment with dapagliflozin reduced death and HF hospitalizations across 
the range of baseline KCCQ values, and improved symptom burden, functional status and quality 
of life in patients with HFrEF. Furthermore, dapagliflozin significantly increased the proportion 
of patients experiencing small, moderate and large improvements in health status; these effects 
were clinically important.   
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Table 1. Baseline characteristics of the KCCQ study population 
 
 
KCCQ-TSS at Baseline 
p-value 
for trend 
Tertile 1 
N=1,487 
Tertile 2 
N=1,564 
Tertile 3 
N=1,392 
Total 
N=4,443 
Age (years) 65.8 (11.0) 66.4 (10.5) 66.8 (10.5) 66.3 (10.7) 0.007 
Sex     <0.001 
    Female 414 (27.8%) 344 (22.0%) 233 (16.7%) 991 (22.3%)  
    Male 1,073 (72.2%) 1,220 (78.0%) 1,159 (83.3%) 3,452 (77.7%)  
Race     <0.001 
    Asian 183 (12.3%) 349 (22.3%) 455 (32.7%) 987 (22.2%)  
    African American 100 (6.7%) 59 (3.8%) 52 (3.7%) 211 (4.7%)  
    White 1,175 (79.0%) 1,141 (73.0%) 864 (62.1%) 3,180 (71.6%)  
    Other 29 (2.0%) 15 (1.0%) 21 (1.5%) 65 (1.5%)  
Geographic Region     <0.001 
    Asia/Pacific 180 (12.1%) 342 (21.9%) 447 (32.1%) 969 (21.8%)  
    Europe 803 (54.0%) 750 (48.0%) 511 (36.7%) 2,064 (46.5%)  
    North America 226 (15.2%) 222 (14.2%) 196 (14.1%) 644 (14.5%)  
    South America 278 (18.7%) 250 (16.0%) 238 (17.1%) 766 (17.2%)  
Systolic BP (mmHg) 121.5 (16.1) 121.4 (16.3) 122.6 (16.4) 121.8 (16.3) 0.102 
Diastolic BP (mmHg) 73.9 (10.1) 73.3 (10.4) 73.5 (10.9) 73.5 (10.5) 0.151 
Pulse (bpm) 72.7 (12.1) 71.0 (11.4) 70.4 (11.4) 71.4 (11.7) <0.001 
Body Mass Index (kg/m2) 29.8 (6.6) 28.0 (5.6) 27.0 (5.2) 28.3 (5.9) <0.001 
Creatinine (mg/dL) 1.2 (0.4) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 0.007 
eGFR  
(mL/min/1.73 m2) 
64.2 (19.1) 65.9 (19.2) 66.9 (19.2) 65.7 (19.2) <0.001 
NT-proBNP (pmol/L) 
1716.2 
(964.0–3274.7) 
1389.0 
(827.8–2517.9) 
1291.6 
(798.9–2172.4) 
1432.0 
(855.1–2635.7) 
<0.001 
Main etiology of HF     0.034 
   Ischemic 865 (58.2%) 886 (56.6%) 755 (54.2%) 2,506 (56.4%)  
   Non-Ischemic 497 (33.4%) 565 (36.1%) 518 (37.2%) 1,580 (35.6%)  
   Unknown 125 (8.4%) 113 (7.2%) 119 (8.5%) 357 (8.0%)  
LVEF (%) 31.2 (6.8) 31.0 (6.8) 31.0 (6.7) 31.1 (6.8) 0.184 
NYHA class     <0.001 
    II 745 (50.1%) 1,108 (70.8%) 1,139 (81.8%) 2,992 (67.3%)  
    III 724 (48.7%) 443 (28.3%) 242 (17.4%) 1,409 (31.7%)  
    IV 18 (1.2%) 13 (0.8%) 11 (0.8%) 42 (0.9%)  
KCCQ-TSS 51.0 (40.6–58.3) 79.2 (72.4–83.3) 97.9 (92.7–100.0) 77.1 (58.3–91.7) <0.001 
Hypertension 1,185 (79.7%) 1,144 (73.1%) 995 (71.5%) 3,324 (74.8%) <0.001 
History of type 2 diabetes 683 (45.9%) 618 (39.5%) 567 (40.7%) 1,868 (42.0%) 0.004 
History of atrial 
fibrillation 
654 (44.0%) 575 (36.8%) 493 (35.4%) 1,722 (38.8%) <0.001 
Prior HF hospitalization 777 (52.3%) 825 (52.7%) 715 (51.4%) 2,317 (52.1%) 0.642 
Prior myocardial 
infarction 
678 (45.6%) 694 (44.4%) 605 (43.5%) 1,977 (44.5%) 0.249 
Prior PCI 476 (32.0%) 547 (35.0%) 511 (36.7%) 1,534 (34.5%) 0.008 
Prior CABG 253 (17.0%) 281 (18.0%) 225 (16.2%) 759 (17.1%) 0.56 
ACEI 818 (55.0%) 887 (56.7%) 781 (56.1%) 2,486 (56.0%) 0.544 
ARB 413 (27.8%) 428 (27.4%) 371 (26.7%) 1,212 (27.3%) 0.501 
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KCCQ-TSS at Baseline 
p-value 
for trend 
Tertile 1 
N=1,487 
Tertile 2 
N=1,564 
Tertile 3 
N=1,392 
Total 
N=4,443 
ARNI 170 (11.4%) 168 (10.7%) 152 (10.9%) 490 (11.0%) 0.654 
Diuretic 1,430 (96.2%) 1,470 (94.0%) 1,260 (90.5%) 4,160 (93.6%) <0.001 
Digoxin 297 (20.0%) 287 (18.4%) 233 (16.7%) 817 (18.4%) 0.025 
Betablocker 1,432 (96.3%) 1,506 (96.3%) 1,336 (96.0%) 4,274 (96.2%) 0.653 
Magnetic resonance 
angiography 
1,098 (73.8%) 1,118 (71.5%) 933 (67.0%) 3,149 (70.9%) <0.001 
Antiplatelet 774 (52.1%) 862 (55.1%) 781 (56.1%) 2,417 (54.4%) 0.028 
Anticoagulant 674 (45.3%) 642 (41.0%) 567 (40.7%) 1,883 (42.4%) 0.012 
Statin 985 (66.2%) 1,054 (67.4%) 944 (67.8%) 2,983 (67.1%) 0.366 
History of ICD 302 (20.3%) 336 (21.5%) 283 (20.3%) 921 (20.7%) 0.975 
CRT-D 94 (6.3%) 96 (6.1%) 90 (6.5%) 280 (6.3%) 0.879 
Cardiac Pacemaker 
CRT-D or CRT-P 
117 (7.9%) 119 (7.6%) 107 (7.7%) 343 (7.7%) 0.852 
History of ICD or CRT-D 396 (26.6%) 432 (27.6%) 373 (26.8%) 1,201 (27.0%) 0.910 
Data are mean (standard deviation), medians (interquartile range) or number (%); ACEI, angiotensin-converting enzyme 
inhibitors; ARB, Angiotensin II receptor blockers; ARNI, angiotensin receptor neprilysin inhibitor; BP, blood pressure; 
CABG, Coronary artery bypass grafting; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac 
resynchronization therapy pacemaker; eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable 
cardioverter defibrillator; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, Left Ventricular Ejection Fraction; 
NT-proBNP, N-terminal pro b-type natriuretic peptide; NYHA, New York Heart Association; PCI, Percutaneous coronary 
intervention; TSS, total symptom score 
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Figure Legends 
Figure 1. Time to first event of cardiovascular death or worsening heart failure according 
to KCCQ-TSS tertile at randomization  
Tertile >87.5: Referent; Tertile 65.7–87.5: HR 1.30 (95%CI: 1.08–1.56), P=0.006; Tertile ≤65.6: 
HR 1.93 (95%CI 1.62–2.30), P<0.001. HR, Hazard ratio; KCCQ, Kansas City Cardiomyopathy 
Questionnaire; TSS, total symptom score. 
Figure 2. Effects of dapagliflozin as compared with placebo on the clinical events across the 
tertiles of KCCQ-TSS at baseline 
KCCQ, Kansas City Cardiomyopathy Questionnaire; TSS, total symptom score; HR, Hazard 
ratio; CI, confidence interval 
Figure 3. Effects of dapagliflozin as compared with placebo on mean (A) KCCQ-TSS, (B) 
KCCQ-CSS and (C) KCCQ-OSS over 8 months of treatment 
Analysis includes those patients that are alive at the time of the KCCQ assessment (i.e. 4 months 
and 8 months). CSS, clinical summary score; KCCQ, Kansas City Cardiomyopathy 
Questionnaire; OSS, overall summary score; TSS, total symptom score 
Figure 4. Responder analyses of clinically meaningful changes in (A, B) KCCQ-TSS, (C, D) 
KCCQ-CSS and – (E, F) KCCQ-OSS with dapagliflozin versus placebo at 8 months 
Deaths are treated as not improved or as deteriorated (for the improvement and deterioration 
calculations, respectively). CI, confidence interval; CSS, clinical summary score; KCCQ, Kansas 
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City Cardiomyopathy Questionnaire; NNT, number-needed-to-treat (numbers in parenthesis 
represent 95% Confidence Intervals); OR, odds ratio; OSS, overall summary score; TSS, total 
symptom score  
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